Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy - Beyond the Abstract
Metastatic castration-resistant prostate cancer (mCRPC) presents significant clinical challenges due to limited treatment options and poor patient outcomes. While prostate-specific membrane antigen (PSMA)-targeted alpha therapy using Actinium-225 (225Ac) …